Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19.
This analysis of phase 3 CANOPY and phase 1 trial data examined measured and calculated serum virus-neutralizing antibody titers after pemivibart in participants with and without significant immunocompromise.
Why it matters
Neutralization against circulating SARS-CoV-2 variants may differ substantially from responses to earlier variants, so prior immune experience does not necessarily imply strong cross-protection.